Biotech Values

[mcbio]

As per usual, I do not believe that such peptide immunotherapeutics elicit a sufficient immune response. I would personally stay away from cldx even if that means I miss out on a phase iii success.

Did you catch the prior Phase 2 data on the breast cancer MAB ( http://ir.celldextherapeutics.com/phoenix.zhtml?c=93243&p=irol-newsArticle&ID=1434911&highlight= )? I think that data was positive and showed activity for the drug. CLDX will present Phase 2b data at ASCO this year. It is an important binary event for CLDX, much more important than anything that happens with rindo IMHO. Market cap is still just ~$140M. Yes, I remain a very biased long. ; )